Industry news

New tuberculosis drug with proven efficacy developed

Marchmont Innovation News

Infectex, a Russian biomed company, has come up with a new drug candidate, designated SQ109, which is “unparalleled elsewhere in the world,” as the developers said. Clinical trials for the candidate were completed in 2017. Infectex claims this is the first new proven drug for tuberculosis in the global market in four decades. 

Russian Ministry amends procedure for licensing the manufacturing of drugs

GMP News

The Ministry of Industry and Trade of Russia amended its Administrative Rules for licensing the manufacturing of medicinal products. According to the Ministry, the relevant order was elaborated and approved to improve the quality of provision, period and availability of results of this public service provided by the Ministry, create comfortable conditions for participants in relations arising during the provision of service for licensing the manufacturing of medicinal products for human use, and defining the period and sequence of activities (administrative procedures).

Russia approves the plan for Development of Biotechnology and Genetic Engineering”

GMP News

The Russian government adopted the action plan (roadmap) for the Development of Biotechnology and Genetic Engineering in 2018 – 2020. The plan aims at developing domestic demand, manufacturing and exports of biotech products, and building institutional environment in order to modernize the technology base of the industry through mass introduction of biotech methods and products.

Pharma ads at the Winter Olympics: 15 brands, but midpack finish for spending share

Beth Snyder Bulik / FiercePharma

Pharma ads skated into the Winter Olympics along with dozens of consumer brand ads, and although they weren’t in any medal contention for time and attention, the category had a respectable showing.

Japan saved $12.2 billion through use of generics

GMP News

Japan’s Ministry of Health, Labour and Welfare (MHLW) suggested that the country’s push to lower prescription costs by switching to generic drugs is forecast to have saved $12.2 billion in fiscal 2017.

Russian-made medicines account for up to 72% of public procurement in Russia

GMP News

In 2017, the public procurement of medicines decreased slightly (with stronger decline in physical rather than monetary terms) and amounted to 340 billion rubles and 0.88 billion packages. These figures were reported in the review of public procurement of medicines for 2017.

07 March 2018

Clearside Announces Pricing of Public Offering of Common Stock

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of  $13.00  per share.  

Pharma's Image Fix: Lessons from the Field

Lisa Henderson / Pharmaceutical Executive

“Pharma is based on a premise that is innovation-driven, which, by definition, means disruptive,” said Galeota. “We tend to think of disruption as agile and fast, but in the case of the pharma industry, many enterprises are more like institutions, and they move slowly; new drug development takes time and care. Ironically, pharmaceutical companies willingly take on risk with development programs, yet are slow to take on risk in other areas like business model evolution, for example. There is a kind of dichotomy; on one hand, there is an appetite for investing heavily in unproven new programs in the labs, but on the other, very little tolerance for novel approaches to how companies are run, go to market, price products, etc.” 

Import substitution leads to growth of drug manufacturing in Russia

GMP News

According to Rosstat, in 2017, the output of medicines was 12.3% higher than in 2016. The drugs for the treatment of nervous system accounted for the largest share in the output of pharmaceutical companies (about 1 billion packages), while the highest growth was reported in the segment of medicines for sense organ diseases. The Russian Ministry of Industry and Trade said that output growth was facilitated by state support to Russian manufacturers.

06 March 2018

Clearside Announces Proposed Public Offering of Common Stock

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it intends to offer and sell, subject to market conditions,  $75 million  of shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Clearside.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.